Novo Nordisk's Diabetes Drug Outshines Ozempic: Buy?
A new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
Some index funds distribute fewer capital gains than others, which can reduce tax surprises and improve after-tax performance over time.
28,126 articlesA new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
Turning Point Brands stock took a sharp drop this week as investors weighed a disappointing quarter and cautious guid...
NVIDIA riding robust AI demand, elevated data-center spending, and resilient margins as 2026 unfolds. Analysts weigh ...
Nvidia has shown accelerating AI-driven demand that could push the stock higher. This article breaks down why the mar...
Nike remains a heavyweight in athletic wear, but its stock has faced pressure. This guide breaks down whether should ...
loandepot reports $108m loss for 2025, reflecting a tougher fourth quarter even as annual revenue and pull-through ma...
Apple’s shares tumbled after WWDC-style AI updates raised questions about iPhone upgrades and monetization. This guid...
A bold move by Oracle in the AI data-center space could reshape demand for NVIDIA GPUs. This article explains what th...
As Micron gears up for its June earnings, a fresh investing angle centers on the idea that prediction: micron stock w...
Meta Platforms is gaining momentum in July 2026 as advertisers lean into AI-powered targeting. This piece explains wh...
Nvidia sits at the heart of AI infrastructure, but its stock faces a potential shift this March. This guide breaks do...
As SoFi expands beyond student loan refi, the question for investors is clear: where will SoFi Technologies be in fiv...